Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.59 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.44 |
| ▸ | KIF11 | P52732 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13439830 | 0.87 | SMPD1 (0.55) | MAOBNR4A2RAB9AAPPSMPD1 | |
| SCHEMBL23235861 | 0.86 | MAOB (0.56) | MAOBNR4A2RAB9AAPPSMPD1 | |
| SCHEMBL13439831 | 0.86 | MAOB (0.52) | MAOBFFAR1FFAR4NR4A2 | |
| SCHEMBL13439790 | 0.85 | FFAR1 (0.56) | MAOBFFAR1FFAR4NR4A2APP | |
| SCHEMBL8756345 | 0.85 | MAOB (0.63) | MAOBFFAR1FFAR4NR4A2RAB9A | |
| SCHEMBL28558200 | 0.84 | MAOB (0.76) | MAOBFFAR1FFAR4RAB9ASMPD1 | |
| SCHEMBL22548672 | 0.83 | MAOB (0.56) | MAOBNR4A2RAB9A | |
| SCHEMBL13439789 | 0.81 | APP (0.66) | MAOBNR4A2RAB9AAPPKIF11 | |
| SCHEMBL23235800 | 0.81 | MRGPRX4 (0.48) | AR | |
| SCHEMBL23235773 | 0.81 | MRGPRX4 (0.51) | MAOBAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230105108-A1 | COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION OF ANTIBIOTICS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2023-04-06 | — | — | US | disclosed |
| EP-4076420-A1 | COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION OF ANTIBIOTICS | Georgia State University Research Foundation, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| WO-2021127452-A1 | COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION OF ANTIBIOTICS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230105108-A1 | COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION OF ANTIBIOTICS | BPGM, MYD88, PGLS | MAOB 2129/4885FFAR1 4278/4885FFAR4 4018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.